PERIPHERAL NEUROPATHY AND NERVE ELECTROPHYSIOLOGICAL CHANGES WITH ENFORTUMAB VEDOTIN IN PATIENTS WITH ADVANCED UROTHELIAL CARCINOMA: A PROSPECTIVE MULTICENTER COHORT STUDY

被引：0
|
作者：
Taoka, Rikiya
Kamada, Masaki
Izumi, Kazuyoshi
Tanimoto, Ryuta
Daizumoto, Kei
Hayashida, Yushi
Uematsu, Katsutoshi
Arai, Hironobu
Sano, Takeshi
Saito, Ryoichi
Hirama, Hiromi
Kobayashi, Toshihiro
Sugimoto, Mikio
机构：
来源：
JOURNAL OF UROLOGY | 2024年 / 211卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP53-14
引用
收藏
页码：E868 / E869
页数：2
相关论文
共 50 条
  • [21] Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective study
    Urabe, Fumihiko
    Taneda, Yuki
    Uchida, Naoki
    Kagawa, Hirokazu
    Muramoto, Katsuki
    Goto, Yuma
    Koike, Yuhei
    Hara, Shuhei
    Ohtsuka, Takashi
    Nakazono, Minoru
    Ishikawa, Mimu
    Imai, Yu
    Iwatani, Kosuke
    Kayano, Sotaro
    Atsuta, Mahito
    Aikawa, Koichi
    Tashiro, Kojiro
    Sasaki, Takaya
    Miki, Jun
    Kimura, Takahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2025,
  • [22] Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real-World Multicenter Study
    Ozaki, Kai
    Yamamoto, Hayato
    Sekine, Yuya
    Horiguchi, Hirotaka
    Hosogoe, Shogo
    Mikami, Jotaro
    Fujita, Naoki
    Tokui, Noriko
    Okita, Kazutaka
    Okamoto, Teppei
    Mori, Kanami
    Kobayashi, Mizuki
    Numakura, Kazuyuki
    Yoneyama, Takahiro
    Tabata, Ryuji
    Sato, Satoshi
    Habuchi, Tomonori
    Ohyama, Chikara
    Hatakeyama, Shingo
    INTERNATIONAL JOURNAL OF UROLOGY, 2025,
  • [23] Enfortumab Vedotin Nursing perspectives on the management of adverse events in patients with locally advanced or metastatic urothelial carcinoma
    Pace, Amanda
    Brower, Blaine
    Conway, Dawn
    Leis, Dayna
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2021, 25 (02) : E1 - E9
  • [24] Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
    Jindal, Tanya
    Kilari, Deepak
    Alhalabi, Omar
    Nizam, Amanda
    Khaki, Ali Raza
    Basu, Arnab
    Barata, Pedro C.
    Bilen, Mehmet Asim
    Shah, Sumit
    Zakharia, Yousef
    Milowsky, Matthew I.
    Bellmunt, Joaquim
    Emamekhoo, Hamid
    Davis, Nancy B.
    Grivas, Petros
    Gupta, Shilpa
    Hoimes, Christopher J.
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [25] Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
    Sayegh, Nicolas
    Jo, Yeonjung
    Gebrael, Georges
    Tripathi, Nishita
    Chigarira, Beverly
    Srivastava, Ayana
    Nordblad, Blake
    Dal, Emre
    Chehade, Chadi Hage
    Mahlow, Jon
    Maughan, Benjamin L.
    Gupta, Sumati
    Agarwal, Neeraj
    Swami, Umang
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [26] Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study
    Minato, Akinori
    Furubayashi, Nobuki
    Nagata, Yujiro
    Tomoda, Toshihisa
    Masaoka, Hiroyuki
    Song, Yoohyun
    Hori, Yoshifumi
    Kiyoshima, Keijiro
    Negishi, Takahito
    Kuroiwa, Kentaro
    Seki, Narihito
    Tomisaki, Ikko
    Harada, Kenichi
    Nakamura, Motonobu
    Fujimoto, Naohiro
    CURRENT ONCOLOGY, 2024, 31 (02) : 862 - 871
  • [27] Editorial comment from Dr Taguchi to Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study
    Taguchi, Satoru
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (04) : 348 - 348
  • [28] EVALUATION OF QTC INTERVAL IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA FOLLOWING ENFORTUMAB VEDOTIN ADMINISTRATION.
    Yamada, A.
    Fukushi, R.
    Kadokura, T.
    Garg, A.
    Tang, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S58 - S58
  • [29] Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China
    Li, Siming
    Shi, Yanxia
    Dong, Haiying
    Guo, Hongqian
    Xie, Yu
    Sun, Zhongquan
    Zhang, Xiaoping
    Kim, Eric
    Zhang, Jun
    Li, Yue
    Xu, Chenming
    Kadeerbai, Haishan
    Lee, Sue
    Gorla, Seema
    Guo, Jun
    Sheng, Xinan
    CANCER MEDICINE, 2024, 13 (21):
  • [30] Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.
    Petrylak, Daniel Peter
    Smith, David C.
    Flaig, Thomas W.
    Zhang, Jingsong
    Sridhar, Srikala S.
    Ruether, Joseph D.
    Plimack, Elizabeth R.
    Merchan, Jaime R.
    Quinn, David I.
    Kilari, Deepak
    Srinivas, Sandy
    Baranda, Joaquina Celebre
    Lang, Joshua Michael
    Milowsky, Matthew I.
    Galsky, Matt D.
    Spira, Alexander I.
    Gartner, Elaina M.
    Wu, Chunzhang
    Melhem-Bertrandt, Amal
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345